Institute for ProgressBiotechnology Fellow
May 2026 — Present
Works on biosecurity and biotechnology policy, including preparation for risks from increasingly capable AI.
1 unread notifications
Olivia H. Scharfman Biosecurity & Biotechnology @IFP. Formerly: Co-founder @ LincSwitch Tx, Principal @ SALT Fund, Biophysics @Yale, Chairman @SEDSusa, @XPRIZE.
Olivia H. Scharfman Biosecurity & Biotechnology @IFP. Formerly: Co-founder @ LincSwitch Tx, Principal @ SALT Fund, Biophysics @Yale, Chairman @SEDSusa, @XPRIZE.
Career
BlueDot ImpactTalent Investor, Biosecurity (contract)
May 2026 — Present
Develops biosecurity strategy and helps researchers and builders work on reducing catastrophic biological risks.
IndependentBiosecurity and Biodefense Consultant
May 2025 — May 2026
Advised on biodefense strategy and policy.
LincSwitch TherapeuticsCo-founder
Nov 2023 — May 2025
Co-founded a biotechnology company focused on long non-coding RNA therapeutics.
SALT FundPrincipal
Jul 2022 — May 2024
Worked in venture investing before co-founding LincSwitch Therapeutics.
Yale School of MedicineResearcher
2021 — 2022
Studied molecular mechanisms of aging in Morgan Levine’s Aging in Living Systems laboratory.
XPRIZEDevelopment and Research Analyst Intern
Feb 2017 — May 2017
Supported research and development work at XPRIZE.
DEKA Research & DevelopmentBiophysics and Electrical Engineering Intern
May 2016 — Aug 2016
Worked on biophysics and electrical engineering research and development.
Cosigns Received
Featured Media
blog.bluedot.org
Biosecurity Strategy
Co-authored with Chris Strahle: a strategy for reducing catastrophic biological risks and directing technical and policy work toward tractable defenses.
ifp.org
How Should the US Prepare for Increasingly Automated AI R&D?
Co-authored IFP report proposing 23 preparatory policies, including biosecurity resilience, to address the risks of AI research automation.